50 completed, 14 recruiting, 6 withdrawn, 3 not yet recruiting. 38 Phase 2, 26 Phase 1, 8 Early Phase 1, 5 Phase 3, 4 Not applicable.
Follow MDMA: new trials by email Literature Review of MDMA trials Research Report on MDMA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders MDMA - Post-Traumatic Stress Disorder, Adjustment Disorders | Phase 2 | Not yet recruiting | Nautilus Sanctuary | 30 | 2026-10-01 | 2026-05-05 |
| MDMA-assisted Therapy for Fibromyalgia MDMA - Fibromyalgia | Early Phase 1 | Recruiting | Spaulding Rehabilitation Hospital | 20 | 2026-09-15 | 2026-08-26 |
| MDMA-Assisted Massed Exposure Therapy for PTSD 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE) - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Emory University | 200 | 2026-07-01 | 2026-05-26 |
| MDMA Therapy in Veterans With PTSD MDMA - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Sunstone Medical | 52 | 2026-06-30 | 2026-07-01 |
| Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls MDMA, Placebo - Autism Spectrum Disorder | Not applicable | Not yet recruiting | University Hospital, Basel, Switzerland | 40 | 2026-06-01 | 2026-04-29 |
| MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function Midomafetamine HCl - Pharmacokinetics, Hepatic Impairment | Phase 1 | Not yet recruiting | Resilient Pharmaceuticals | 16 | 2026-03-29 | 2024-10-30 |
| A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders Midomafetamine, Non-directive therapy, Therapy - Anorexia Nervosa Restricting Type, Binge-Eating Disorder | Phase 2 | Withdrawn | Resilient Pharmaceuticals | 2026-02-01 | 2024-10-31 | |
| Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial 3,4-Methylenedioxymethamphetamine, Methylphenidate - Chronic Neuropathic Pain | Phase 2 | Recruiting | Unity Health Toronto | 50 | 2026-01-30 | 2026-07-29 |
| A Phase 2A Trial of DT402 for Autism Spectrum Disorder DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) - Autism Spectrum Disorder, ASD | Phase 2 | Recruiting | Definium Therapeutics US, Inc. | 20 | 2025-12-03 | 2026-09-02 |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) Psilocybin, MDMA - Posttraumatic Stress Disorder | Phase 1 | Recruiting | Johns Hopkins University | 40 | 2025-09-17 | 2026-09-04 |
| MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) 3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT) - Obsessive-Compulsive Disorder | Phase 2 | Recruiting | Carolyn Rodriguez | 40 | 2025-09-10 | 2026-03-05 |
| MDMA in Borderline Personality Disorder MDMA - Borderline Personality Disorder | Phase 2 | Recruiting | Yale University | 10 | 2025-09-05 | 2026-10-22 |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents MDMA, Psychotherapy - PTSD, Post Traumatic Stress Disorder, Adolescents | Phase 2 | Withdrawn | University of California, Los Angeles | 2025-07-01 | 2025-04-10 | |
| Dose Optimization of MDMA-Assisted Therapy for PTSD Midomafetamine, Psychotherapy - Posttraumatic Stress Disorder | Phase 2 | Recruiting | Bronx VA Medical Center | 60 | 2025-06-03 | 2026-10-08 |
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder 3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy - Post Traumatic Stress Disorder | Phase 2 | Recruiting | Stephen Robert Marder | 40 | 2025-03-01 | 2026-08-19 |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder MDMA, Cognitive Processing Therapy, MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) - PTSD | Phase 2 | Recruiting | Patricia Suppes | 30 | 2025-02-10 | 2025-07-31 |
| Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls MDMA, Placebo - Central Diabetes Insipidus | Not applicable | Recruiting | University Hospital, Basel, Switzerland | 24 | 2025-01-27 | 2025-02-19 |
| Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2) Midomafetamine HCl, Therapy - Psychological Effects of Study Drug | Phase 1 | Withdrawn | Resilient Pharmaceuticals | 2024-12-01 | 2024-10-31 | |
| MDMA-assisted Massed Prolonged Exposure for PTSD 3,4 Methylenedioxymethamphetamine, Prolonged Exposure - Post-Traumatic Stress Disorder | Phase 3 | Active not recruiting | Healing Breakthrough | 20 | 2024-10-25 | 2026-08-26 |
| The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. MDMA, Niacin - Post Traumatic Stress Disorder | Phase 1 | Withdrawn | Yale University | 2024-05-01 | 2026-05-19 |
Showing 20 of 82. Sign in to see all of them.
Stress Disorders, Post-Traumatic (38) · Substance-Related Disorders (11) · Amphetamine-Related Disorders (7) · Mood Disorders (7) · Alcoholism (3) · Autism Spectrum Disorder (3) · Adjustment Disorders (2) · Anxiety Disorders (2) · Combat Disorders (2) · Autistic Disorder (1) · Binge-Eating Disorder (1) · Borderline Personality Disorder (1) · Chronic Pain (1) · Coitus (1) · Depression (1)
Resilient Pharmaceuticals (27) · University Hospital, Basel, Switzerland (17) · University of Chicago (5) · Emory University (2) · Parc de Salut Mar (2) · Sunstone Medical (2) · Yale University (2) · Bronx VA Medical Center (1) · Carolina L Haass-Koffler (1) · Carolyn Rodriguez (1) · Definium Therapeutics US, Inc. (1) · Germans Trias i Pujol Hospital (1) · Guy Schusheim (1) · Healing Breakthrough (1) · Imperial College London (1)
United States (45) · Switzerland (19) · Canada (6) · Israel (6) · Spain (3) · United Kingdom (2) · Australia (1) · Czechia (1) · Germany (1) · Netherlands (1) · Norway (1)
Matthias E Liechti, MD (9) · Matthias E Liechti, MD, MAS (4) · Michael C Mithoefer, MD (4) · Harriet de Wit (2) · Jessica Maples-Keller, PhD (2) · Manish Agrawal, MD (2) · Matthias E Liechti, Prof. Dr. MD (2) · Michael Mithoefer, MD (2) · Moshe Kotler (2) · Adele Lafrance, PhD (1) · Akash Goel, MD,MPH,FRCPC (1) · Alison Bruni, MD (1) · Amy Lehrner, PhD (1) · Anne Wagner, PhD (1) · Barbara O Rothbaum, PhD (1)
PMID 29912955, PMID 31065731, PMID 31572236, PMID 32500209, PMID 22700038, PMID 33972795, PMID 18794647, PMID 20643699, PMID 21456632, PMID 21715530, PMID 22574166, PMID 23112822, PMID 23118021, PMID 23172889, PMID 23857311, PMID 24103254, PMID 25818246, PMID 27206266, PMID 28551715, PMID 28722422, PMID 29728331, PMID 30196397, PMID 33235285, PMID 35166140, PMID 35910354, PMID 36405923, PMID 36713926, PMID 36815187, PMID 36873994, PMID 37258715, PMID 37520237, PMID 37709999, PMID 38174611, PMID 38198456, PMID 39179638, PMID 39262902, PMID 39895858, PMID 40305021, PMID 40492610, PMID 40999236, PMID 41947855, PMID 42049943, PMID 42409408
2016 (1), 2025 (1), P50DA042012 (1), R01DA002812 (1), R01DA017987 (1)